Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSErythropoiesis is the process of formation of red blood cells. The process is initiated with the help of a hormone known as erythropoietin, which is released by the kidneys and stimulates the bone marrow in order to synthesize more blood cells. Erythropoietin stimulating agents are drugs which work in a manner similar to erythropoietin and are taken in order to increase the number of blood cells in the body. This is usually done in cases of anemia caused as a result of various health diseases such as cancer, blood disorders, neural disorders, chronic kidney disease, HIV and several others.
The erythropoietin stimulating agents market is anticipated to record a significant CAGR over the forecast period i.e. 2020–2028. The market is segmented by agent, by application and by region, out of which, the application segment is further divided into cancer, neural disorders, kidney disorders, anemia and others.
According to Centers for Disease Control and Prevention (CDC), 15% of total number of adults in the United States, i.e., around 37 million people were estimated to have chronic kidney disease in 2019.
On the basis of this, the kidney disorders segment is anticipated to hold the largest share in the market as a result of erythropoietin stimulating agents being used for the treatment of anemia among patients with chronic kidney disease. Additionally, the cancer segment is anticipated to hold a significant share in the erythropoietin stimulating agents market on account of growing use of erythropoietin for improving anemia in cancer patients. Data presented by the World Bank indicated that the prevalence of anemia among women between 15 and 49 years, i.e., of the reproductive age, is 32.8% in the world. Cancer-associated anemia interferes with cancer therapies, including chemotherapy, which increases the demand for these agents.
Chronic Kidney Disease is more common in older people aged 65 and above, with 38% prevalence, as compared with people aged 18-44 years (7%) and 45-64 years (13%) in the United States as per the CDC. The rising cases of this disorder along with other renal disorders that have a direct impact on the blood cells results in an increased demand for erythropoietin stimulating agents. Moreover, the growing incidences of various types of cancers, especially blood cancers, is another factor resulting in a high demand for blood cells in the body. These factors are anticipated to lead to the market growth over the forecast period. According to the statistics presented by the Leukemia & Lymphoma Society, it was suggested that a total of 176,200 people living in the United States were expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. CLICK TO DOWNLOAD SAMPLE REPORT
Numerous pharmaceutical manufacturers are taking initiatives to develop and produce erythropoietin stimulating agents (ESAs) after the expiration of Amgen’s patent for Epogen. The growing commercialization of these drugs further results in reduction of their prices. This is anticipated to become another growth factor for the market in the upcoming years.
Erythropoietin stimulating agents have been known to exhibit certain side effects in patients taking them as drugs. These might include, fever, swelling, high blood pressure, nausea, dizziness and pain at the injection site. This is estimated to restrict the market growth during the forecast period.
Our in-depth analysis of the erythropoietin stimulating agents market includes the following segments:
On the basis of regional analysis, the erythropoietin stimulating agents market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific is anticipated to expand at the highest rate on account of growing developments and innovations in the field of medicine in the region. Moreover, the rising purchasing power of people and growth in medical tourism are anticipated to lead to the market growth as well. Erythropoietin stimulating agents have displayed high effectiveness when used in the treatment of various disorders such as neural disorders, cancer, chronic kidney disease (CKD) and anemia, among several others. The market for erythropoietin stimulating agents in North America is estimated to hold the largest share in the global market on account of high occurrence of various disorders that eventually cause anemia in the region.
The erythropoietin stimulating agents market is further classified on the basis of region as follows:
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
